- Home
- IGAC vs CABA Comparison
IGAC vs CABA Comparison
Compare IGAC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGAC | CABA |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.3M | 319.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | IGAC | CABA |
|---|---|---|
| Price | $9.94 | $3.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 13.1K | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $0.99 |
| 52 Week High | $9.99 | $3.78 |
Technical Indicators
Market Signals| Indicator | IGAC | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 63.63 |
| Support Level | $9.92 | $2.11 |
| Resistance Level | $9.99 | $3.73 |
| Average True Range (ATR) | 0.01 | 0.30 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 29.11 | 69.26 |
Price Performance
Historical ComparisonAbout IGAC Invest Green Acquisition Corporation Class A Ordinary Shares
Invest Green Acquisition Corp is a blank check company.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.